
Ozenoxacin-Induced Contact Dermatitis With Tolerance to Ciprofloxacin

Otero-Fernández MN¹, Laffond-Yges E^{1,2,3,4}, Castillo-Loja RM^{1,2}, Cabrera-Núñez A¹, Mazoterías-Martínez ME¹, Muñoz-Bellido FJ^{1,2,3,4}, Dávila I^{1,2,3,4}

¹Complejo Asistencial Universitario de Salamanca, Salamanca, Spain

²Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain

³Departamento de Ciencias Biomédicas y del Diagnóstico, Universidad de Salamanca, Salamanca, Spain

⁴Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0002/0054), Red de Enfermedades Inflamatorias (REI), Instituto de Salud Carlos III, Madrid, Spain

J Investig Allergol Clin Immunol 2025; Vol. 35(1): 72-73
doi: 10.18176/jiaci.1031

Key words: Ozenoxacin. Allergic contact dermatitis. Cross-reactivity. Ciprofloxacin.

Palabras clave: Ozenoxacino. Dermatitis alérgica de contacto. Reactividad cruzada. Ciprofloxacino.

Ozenoxacin is a new nonfluorinated quinolone antimicrobial with high bactericidal potency against *Staphylococcus* and *Streptococcus* species. It has been approved for topical treatment of impetigo in adults and children aged over 6 months [1-3]. Clinical trials have revealed an excellent tolerance and safety profile [1-4]. Cross-reactivity with other quinolones is unknown.

We present the case of a 73-year-old woman who, after receiving topical treatment with Ozanex for an infected wound, gradually developed pruritic dermatitis around the treated area. Ozanex contains ozenoxacin 1%, macrogol stearate, ethylene glycol monopalmitostearate, oleoyl macrogol glycerides, octyldodecanol, stearyl alcohol, propylene glycol, and benzoic acid. One week after discontinuing Ozanex, the patient was prescribed topical Menaderm Simple (beclomethasone), and the reaction subsided 8 days later. Importantly, this was the patient's first exposure to Ozanex. Written informed consent was obtained from the patient for the allergy work-up and publication of this report.

Patch tests were performed with Ozanex and Menaderm Simple as-is, the standard series (T.R.U.E. test), and available vehicles (stearyl alcohol [30% pet], benzyl alcohol [1% pet], benzoic acid [5% pet], propylene glycol [5% pet]). To assess contact sensitization to macrogols, patch tests were performed with polyethylene glycol 400 [100%], polyethylene glycol 4000 [50%], Tween 40 [10% pet], and Tween 80 [10% pet]. Sensitization to octyldodecanol was ruled out due to tolerance to topical application of products containing that substance. Patch tests were positive exclusively for Ozanex at 48 (++) and 96 (++) hours.

To assess cross-reactivity with other quinolones, patch tests were performed with ciprofloxacin (10% pet), levofloxacin (20% pet), and moxifloxacin (10% pet). All the results were negative. A challenge test with oral ciprofloxacin 500 mg showed systemic tolerance at therapeutic doses.

To our knowledge, we present the first published case of delayed hypersensitivity to ozenoxacin. Sensitization to excipients was ruled out as a cause of the reaction, and irritant dermatitis seems highly unlikely owing to the persistent positivity of patch tests at 96 hours. Occlusive patch testing with 1% and 2% ozenoxacin and with repeated doses in healthy volunteers has shown a high tolerability profile [1,2,4]. Furthermore, no cross-reactivity between ozenoxacin and ciprofloxacin has been found.

Funding

The authors declare that no funding was received for the present study.

Conflicts of Interest

In the last 3 years, Ignacio Dávila has received payment for lectures, including service on speaker's bureaus from Allergy Therapeutics, ALK, AstraZeneca, Chiesi, Diater, GSK, Leti, Novartis, and Sanofi. He has also received fees for consultancy from Allergy Therapeutics, ALK-Abello, AstraZeneca, GSK, MSD, Novartis, and Sanofi and grants from ThermoFisher Diagnostics, ISCIII, and Junta de Castilla y León. The remaining authors declare that they have no conflicts of interest.

References

1. Torrelo A, Grimalt R, Masramon X, Albareda López N, Zsolt I. Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents. *Dermatology*. 2020;236(3):199-207.
2. Rosen T, Albareda N, Rosenberg N, Alonso FG, Roth S, Zsolt I, et al. Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients with Impetigo: A Randomized Clinical Trial. *JAMA Dermatol*. 2018;154(7):806-13.
3. Vila J, Hebert AA, Torrelo A, López Y, Tato M, García-Castillo M, et al. Ozenoxacin: a review of preclinical and clinical efficacy. *Expert Rev Anti Infect Ther*. 2019;17(3):159-68.
4. Gropper S, Cepero AL, Dosik JS, LaStella P, Siemetzki H, Wigger-Alberti W. Cumulative irritation, sensitizing potential, phototoxicity and photoallergy of ozenoxacin in healthy adult volunteers. *Future Microbiol*. 2014;9(8 Suppl):S23-31.

■ *Manuscript received June 28, 2024; accepted for publication August 19, 2024.*

María Elena Laffond-Yges

Servicio de Alergología, Complejo Asistencial Universitario
de Salamanca
Paseo de San Vicente, 58
37007 Salamanca, Spain
E-mail: mlaffond@saludcastillayleon.es